ProfileGDS5678 / 1438661_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 84% 80% 84% 80% 79% 76% 74% 81% 82% 80% 82% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9526482
GSM967853U87-EV human glioblastoma xenograft - Control 25.9569782
GSM967854U87-EV human glioblastoma xenograft - Control 36.1938784
GSM967855U87-EV human glioblastoma xenograft - Control 45.8261380
GSM967856U87-EV human glioblastoma xenograft - Control 56.2155784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4411680
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4397479
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0652976
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8569374
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7884981
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9033282
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.746180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8851382
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0215283